Pfizer Inc :Pfizer And Biontech Provide Update On Rolling Submission To European Medicines Agency For A Potential Variant-Adapted Vaccine.Pfizer Inc - Rolling Review Is Initially Based On Chemistry, Manufacturing, And Controls (Cmc) Data Shared With Ema Earlier This Month.Pfizer Inc - Companies Also Plan To Begin Submission Of Data Supporting A Potential Variant-Adapted Vaccine To The U.S. Fda In The Coming Weeks.Pfizer Inc - As Clinical Data Become Available, Including Data On Immunogenicity Against Omicron, Subvariants, Will Be Added To Rolling Submission.Pfizer - Composition Of Variant-Adapted Vaccine To Be Discussed With Regulatory Bodies To Determine Potential Vaccine Booster Approach For Fall 2022.Further Company Coverage: Pfe.N. ((Reuters.Briefs@Thomsonreuters.Com;)).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments